Altimmune, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Altimmune, Inc. on April 16, 2026. The report details the outcomes of the Company's 2026 Annual Meeting of Stockholders held on the same date and the subsequent amendment to its Certificate of Incorporation.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The filing text does not provide a clear value for these metrics.
Material Changes and Corporate Actions
- Authorized Share Increase: The Company amended its Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000.
- Shareholder Participation: As of the record date (March 13, 2026), 130,105,177 shares were outstanding. A total of 88,270,365 shares (67.8%) were present or represented by proxy, establishing a quorum.
- Director Elections: All nine director nominees were elected. Significant broker non-votes (35,855,584 shares) were recorded for each nominee, though "For" votes exceeded "Withhold" votes in all cases.
- ESPP Amendment: Shareholders approved an amendment to the 2019 Employee Stock Purchase Plan, increasing reserved shares from 403,500 to 1,108,827.
Voting Results and Management Commentary
The following proposals were approved by shareholders:
- Proposal 1 (Directors): All nominees received majority support. For example, Jerome Durso received 47,577,875 "For" votes versus 4,836,906 "Withhold" votes.
- Proposal 2 (Auditor Ratification): Ernst & Young LLP was ratified with 84,959,584 "For" votes against 1,771,538 "Against" votes.
- Proposal 3 (Say-on-Pay): The advisory vote on executive compensation passed with 39,928,184 "For" votes against 12,026,081 "Against" votes.
- Proposal 4 (Authorized Shares): The increase in authorized shares was approved with 63,684,172 "For" votes against 24,151,522 "Against" votes.
- Proposal 5 (ESPP): The ESPP amendment passed with 43,616,919 "For" votes against 8,572,159 "Against" votes.
- Proposal 6 (Adjournment): Authorization to adjourn the meeting to solicit additional proxies was approved with 68,318,332 "For" votes.
The filing does not contain specific management commentary, forward-looking guidance, or discussion of risks and contingencies beyond the standard disclosure of the voting results.
Investor Verification Checklist
- Verify the effective date of the Certificate of Amendment filed with the Delaware Secretary of State.
- Review the Company's most recent 10-K or 10-Q for current financial health, as this 8-K contains no financial data.
- Monitor future filings for any capital raises utilizing the newly authorized 200 million additional shares.
- Confirm the updated share count and capitalization table following the ESPP amendment.